참고문헌
- DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
- Lee SY, Park JY. Personalized therapy in lung cancer: focused on molecular targeted therapy. J Lung Cancer 2011;10:1-12. https://doi.org/10.6058/jlc.2011.10.1.1
- Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
- Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, v.3. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
- Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001;12:23-7.
피인용 문헌
- Drug rechallenge and treatment beyond progression-implications for drug resistance vol.10, pp.10, 2012, https://doi.org/10.1038/nrclinonc.2013.158
- Rechallenge Strategy in Cancer Therapy vol.98, pp.10, 2012, https://doi.org/10.1159/000507816